SG11201804160SA - Composition for inhibiting carnosine dipeptidase - Google Patents

Composition for inhibiting carnosine dipeptidase

Info

Publication number
SG11201804160SA
SG11201804160SA SG11201804160SA SG11201804160SA SG11201804160SA SG 11201804160S A SG11201804160S A SG 11201804160SA SG 11201804160S A SG11201804160S A SG 11201804160SA SG 11201804160S A SG11201804160S A SG 11201804160SA SG 11201804160S A SG11201804160S A SG 11201804160SA
Authority
SG
Singapore
Prior art keywords
composition
carnosine
inhibiting
dipeptidase
carnosine dipeptidase
Prior art date
Application number
SG11201804160SA
Inventor
Shinya Fukizawa
Hiroshi Watanabe
Keiichi Abe
Original Assignee
Suntory Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd filed Critical Suntory Holdings Ltd
Publication of SG11201804160SA publication Critical patent/SG11201804160SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pyrane Compounds (AREA)

Abstract

COMPOSITION FOR INHIBITING CARNOSINE DIPEPTIDASE An object of the present invention is to provide a carnosine dipeptidase inhibiting composition, use of said composition for inhibiting carnosine dipeptidases, and a method for inhibiting carnosine dipeptidases. Another object of this invention is to provide a composition that is high in biological safety and is capable of enhancing the actions and effects of carnosine through the use of carnosine dipeptidase inhibitory effect. It was found that particular compounds such as polyphenols have carnosine dipeptidase inhibitory effect. This invention provides an effective and novel means that contributes to, for example, suppression of a rise in blood glucose levels.
SG11201804160SA 2015-12-16 2016-12-16 Composition for inhibiting carnosine dipeptidase SG11201804160SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015245446 2015-12-16
JP2015245449 2015-12-16
PCT/JP2016/087476 WO2017104777A1 (en) 2015-12-16 2016-12-16 Composition for inhibiting carnosine dipeptidase

Publications (1)

Publication Number Publication Date
SG11201804160SA true SG11201804160SA (en) 2018-06-28

Family

ID=59056714

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201804160SA SG11201804160SA (en) 2015-12-16 2016-12-16 Composition for inhibiting carnosine dipeptidase
SG10201912979UA SG10201912979UA (en) 2015-12-16 2016-12-16 Composition for inhibiting carnosine dipeptidase

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912979UA SG10201912979UA (en) 2015-12-16 2016-12-16 Composition for inhibiting carnosine dipeptidase

Country Status (4)

Country Link
JP (1) JPWO2017104777A1 (en)
SG (2) SG11201804160SA (en)
TW (1) TW201733619A (en)
WO (1) WO2017104777A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019043846A1 (en) 2017-08-30 2019-03-07 大塚製薬株式会社 Kaempferol analog-containing composition
WO2020085459A1 (en) * 2018-10-26 2020-04-30 国立大学法人東京大学 Antioxidation agent, antiglycation agent or anti-inflammatory agent
JP7356808B2 (en) * 2019-03-04 2023-10-05 株式会社ノエビア Skin external preparations
JP2020183346A (en) * 2019-04-26 2020-11-12 ロート製薬株式会社 Oral composition
CN114209851B (en) * 2021-12-17 2023-08-29 同济大学 Curcumin-silicon oxide nano drug-loading system and preparation method and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2811353B2 (en) * 1990-07-06 1998-10-15 ゼリア新薬工業株式会社 Inflammatory bowel disease preventive and therapeutic agent
JPH07223940A (en) * 1994-02-14 1995-08-22 Pola Chem Ind Inc Active oxygen eliminating agent and composition containing the same
JP4082823B2 (en) * 1999-05-06 2008-04-30 日本メナード化粧品株式会社 Phototoxicity inhibitor
JP4719372B2 (en) * 2000-06-21 2011-07-06 花王株式会社 PPAR-dependent gene transcription activator
JP2002293736A (en) * 2001-03-30 2002-10-09 Sunstar Inc Maillard reaction inhibitor and composition containing the same
JP2003212774A (en) * 2002-01-22 2003-07-30 Ichimaru Pharcos Co Ltd Maillard reaction inhibitor
AU2003237379A1 (en) * 2002-06-10 2003-12-22 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
US20060116328A1 (en) * 2003-01-20 2006-06-01 Babizhayev Mark A Combined use of carnosinase inhibitor with l-carnosines and composition
JP2005104850A (en) * 2003-09-26 2005-04-21 Kanazawa Univ Tlo Inc Therapeutic agent and prophylactic agent for alzheimer's disease
JP5089025B2 (en) * 2004-04-30 2012-12-05 東海物産株式会社 Antioxidant composition
JP2006160721A (en) * 2004-11-09 2006-06-22 Kao Corp Agent for recovery from fatigue of cerebrum
WO2007116987A1 (en) * 2006-03-31 2007-10-18 Nippon Meat Packers, Inc. Functional food and drug having learning function-improving effect and antidepressant effect
EP1982707A1 (en) * 2007-04-18 2008-10-22 DSMIP Assets B.V. Use of hydroxytyrosol as anti-aging agent
JPWO2009136587A1 (en) * 2008-05-08 2011-09-08 株式会社カネカ Anti-fatigue composition
JP2013107852A (en) * 2011-11-21 2013-06-06 Morishita Jintan Co Ltd Maillard reaction inhibitor
JP6224899B2 (en) * 2013-03-07 2017-11-01 森永製菓株式会社 Hypoglycemic agent

Also Published As

Publication number Publication date
SG10201912979UA (en) 2020-02-27
TW201733619A (en) 2017-10-01
JPWO2017104777A1 (en) 2018-10-04
WO2017104777A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
PH12018501378A1 (en) Compositions and methods for the treatment of hemoglobinopathies
MX2018008052A (en) Lsd1 inhibitors.
SG10201809153WA (en) Muscle atrophy inhibitor containing quercetin glycoside
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
SG11201804160SA (en) Composition for inhibiting carnosine dipeptidase
MX2019001125A (en) Macrocycle kinase inhibitors.
JO3558B1 (en) Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
MX2017003966A (en) Cleaning and/or treatment compositions comprising malodor reduction compositions.
MX2016002075A (en) Ido inhibitors.
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
MX2018006632A (en) Bicyclic inhibitors of pad4.
MX2015011374A (en) Inhibitors of indoleamine 2,3-dioxygenase (ido).
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017000980A (en) Treatment compositions.
MX2017000976A (en) Treatment compositions.
MX2017001290A (en) Fabric treatment composition comprising an aminosiloxane polymer nanoemulsion.
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
MX2018006700A (en) Aza-benzimidazole inhibitors of pad4.
MX2020001793A (en) Ahr inhibitors and uses thereof.
WO2013120022A3 (en) Treatment of hypoglycemia
PH12017501864A1 (en) Compositions and methods for treating autism
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MA39824A (en) Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2
MX2021006326A (en) Pcna inhibitors.
GEP20186920B (en) Halogenated quinazolinthf-amines as pde1 inhibitors